The investigation of safety and efficacy of short hydration GC therapy in metastatic urothelial carcinoma patients
Phase 4
Recruiting
- Conditions
- advanced or metastatic urothelial carcinoma patients
- Registration Number
- JPRN-UMIN000032901
- Lead Sponsor
- agoya City University Graduate School of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
1. patients who had allergy in gemcitabine 2. patients who had allergy in cisplatin 3. previously treated patients by gemcitabine, or cisplatin 4. patients who had sign of interstitial pneumoniae or pulmonary fibrosis 5. patients previously treated in chest by radiation therapy 6. patients who have infection or fever 7. pregnant patients 8. patients giving lactation 9. patients including severe diseases 10. unadequate patients
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method adverse events
- Secondary Outcome Measures
Name Time Method physiological items CBC blood examination serum CRP level renal function ex, eGFR response rate secondary adverse events QOL estimation activity estimated by Fitbits